

## HEPATITIS C THERAPY PRIOR AUTHORIZATION FORM

Incomplete forms will be returned 1-800-492-5231-Option 3 Fax form to 410-333-5398

## Please attach copies of the patient's medical history summary, lab and genetic test reports to the State. \*\*Please review our clinical criteria before submitting this form. \*\*

**Patient Information** Recipient: MA#: Date of Birth: \_\_\_\_\_\_ Phone #: ( ) \_\_\_\_\_ - \_\_\_\_ Body Weight: \_\_\_\_\_ kg Treatment Take \_\_\_\_\_ daily for \_\_\_\_\_ weeks Take \_\_\_\_\_\_daily for \_\_\_\_\_ weeks Take \_\_\_\_\_ daily for \_\_\_\_\_ weeks Adherence with prescribed therapy is a condition for payment of therapy for up to the allowed timeframe for each HCV genotype. Has a treatment plan been developed and discussed with patient? □ No □ Yes Does the patient have any history of medication non-adherence? 

No Yes; If yes, please explain below: **Diagnosis** □ Acute Hep C □ Chronic Hep C □ Hepatocellular Carcinoma ☐ Liver transplant recipient: Genotype of pre-transplant liver: \_\_\_\_\_ Genotype of post-transplant liver: □ Other: What is the patient's HCV genotype and subtype? Has a liver biopsy been performed? □ No □ Yes; Test date : \_\_\_\_\_/\_\_\_\_\_/ Has a fibrosis test been performed: □ No □ Yes; Test used: \_\_\_\_\_; Test date : \_\_\_\_/\_\_\_\_ Metavir Grade: \_\_\_\_\_; Metavir Stage: \_\_\_\_\_ What best describes this patient's liver disease? (Check all that apply): □ No cirrhosis □ Compensated cirrhosis □ Decompensated liver disease \*\*Please provide a copy of the results of the biopsy, genotype and any other fibrosis tests for this patient. \*\*

**Hepatitis C Treatment History** 

| If Treatment Experienced, what w  | as the outcome of the previous treatr   | ments:  |                     |
|---|---|---|---------------------|
| □ Relapsed  | □ Partial Responder □ Non-Re  | esponder 🗆 Toxi   | cities              |
| Please indicate what prior regimen  | n(s) the patient has been treated with:   |   |                     |
| HCV regimen   | Treatment duration/ dates   | Treatment Outcome   |                     |
|   |   | □ Relapsed □ Non-Responder □ Other: □ Relapsed  | □ Partial Responder |
|   |   | □ Non-Responder □ Other:  | $\Box$ I oxicities  |
|   | Laboratory Resul  | ts  |                     |
| Raseline HCV RNA level (up to and   | including 90 days prior to treatment):  | Date  | / /                 |
| For all regimens please attach AST, A   |   | Datc  |                     |
| •   | Sovaldi, Harvoni® or Epclusa ®, please  | attach serum creatinine A   | ND/OR eGFR          |
|   | ribavirin, please attach hemoglobin, hem  |   |                     |
|   | Medical History   | F   |                     |
| s the patient co-infected with HIV  | •   | -   | ad?                 |
| s the patient co-infected with HB   | Date drawn:   | <u> </u>  | oad?                |
|   | er viral infection:  splant?  No  Yes; If yes, specify  Date of transplant:   | what type of transplan  | t:                  |
|   | Substance Use Histo   |   |                     |
| Does the patient have an active di  | agnosis of a substance use disorder?  | □ Yes □ No  |                     |
| If Yes, is the patient actively engal If No, please indicate whether an □Yes □No          | ged in treatment? □ Yes □ No; adherence assessment has been done  | to assure successful tre  | eatment completion: |
| drug assistance, is the physician p<br>therapy?   Yes  I certify that the benefits of the | y changes during therapy and the patirepared to enroll the patient in other patient outweigh treatment for this patient outweigh daccurate to the best of my knowle | patient assistant drug protection the risks and verify the tricks and verify the tricks are the risks and verify the tricks are the risks are | rograms to complete |
| Prescriber's signature  | Prescriber's Name   |   | Date                |
| Telephone# () –   | Fax   | # ()  |                     |
| Practice Specialty:   |   |   |                     |
| Address:  |   |   |                     |
| MDH100518   |   |   |                     |

(DHMH 10/1/2018) Page 2 of 2